| Dr Michael Alleva, MD | |
|
10721 Queens Blvd, Forest Hills, NY 11375-4413 | |
| (718) 575-3322 | |
| (718) 268-1920 |
| Full Name | Dr Michael Alleva |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 41 Years |
| Location | 10721 Queens Blvd, Forest Hills, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730147182 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 160219 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ent And Allergy Associates Llp | 0749193662 | 368 |
News Archive
bluebird bio an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.
Polo Biology Global Group Corporation today announced its financial results for the three months and twelve months ended December 31, 2010.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.
The key to future HIV treatment could be hidden right in our own genes. Everyone who becomes infected deploys defense strategies, and some even manage to hold the virus at bay without any therapy at all.
Mount Sinai researchers have found that myocardial injury (heart damage) is prevalent among patients hospitalized with COVID-19 and is associated with higher risk of mortality.
› Verified 5 days ago
| Entity Name | Ent And Allergy Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376598326 PECOS PAC ID: 0749193662 Enrollment ID: O20031107000043 |
News Archive
bluebird bio an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.
Polo Biology Global Group Corporation today announced its financial results for the three months and twelve months ended December 31, 2010.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.
The key to future HIV treatment could be hidden right in our own genes. Everyone who becomes infected deploys defense strategies, and some even manage to hold the virus at bay without any therapy at all.
Mount Sinai researchers have found that myocardial injury (heart damage) is prevalent among patients hospitalized with COVID-19 and is associated with higher risk of mortality.
› Verified 5 days ago
| Entity Name | Ear, Nose & Throat Associates Of New York,p.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124079769 PECOS PAC ID: 0143111328 Enrollment ID: O20040324001573 |
News Archive
bluebird bio an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.
Polo Biology Global Group Corporation today announced its financial results for the three months and twelve months ended December 31, 2010.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.
The key to future HIV treatment could be hidden right in our own genes. Everyone who becomes infected deploys defense strategies, and some even manage to hold the virus at bay without any therapy at all.
Mount Sinai researchers have found that myocardial injury (heart damage) is prevalent among patients hospitalized with COVID-19 and is associated with higher risk of mortality.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Alleva, MD 660 White Plains Rd Ste 400, Tarrytown, NY 10591-5107 Ph: (914) 984-2546 | Dr Michael Alleva, MD 10721 Queens Blvd, Forest Hills, NY 11375-4413 Ph: (718) 575-3322 |
News Archive
bluebird bio an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.
Polo Biology Global Group Corporation today announced its financial results for the three months and twelve months ended December 31, 2010.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.
The key to future HIV treatment could be hidden right in our own genes. Everyone who becomes infected deploys defense strategies, and some even manage to hold the virus at bay without any therapy at all.
Mount Sinai researchers have found that myocardial injury (heart damage) is prevalent among patients hospitalized with COVID-19 and is associated with higher risk of mortality.
› Verified 5 days ago
Ludvika Hoppenstand, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 9610 Metropolitan Ave, Forest Hills, NY 11375 Phone: 718-459-0400 Fax: 718-286-3863 | |
Allan A Levin, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 11120 Queens Blvd, Forest Hills, NY 11375 Phone: 718-830-0707 Fax: 718-544-4240 | |
Grigoriy Mashkevich, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 10812 72nd Ave Ste 3, Forest Hills, NY 11375 Phone: 718-544-9300 Fax: 718-544-9301 | |
Prof. Abraham Shulman, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 118 35 Queens Blvd., Suite 1430, Forest Hills, NY 11375 Phone: 718-773-8888 Fax: 718-465-3669 | |
Sheldon Paul Hersh, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 11011 72nd Ave, Suite 1b, Forest Hills, NY 11375 Phone: 718-261-9000 Fax: 718-268-0504 | |
Dr. Stephen Warman, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 10721 Queens Blvd, Forest Hills, NY 11375 Phone: 718-575-3322 Fax: 718-268-1920 |